Xilio Therapeutics, Inc.
XLO
$0.6844
-$0.0154-2.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.21% | 23.47% | 23.77% | 22.67% | 22.22% |
| Total Depreciation and Amortization | -9.07% | -7.92% | -13.47% | -11.44% | -7.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.87% | -18.71% | -14.64% | -8.09% | -4.52% |
| Change in Net Operating Assets | -15.98% | 778.41% | 2,016.83% | 2,370.08% | 858.93% |
| Cash from Operations | 23.16% | 139.17% | 73.22% | 75.96% | 78.31% |
| Capital Expenditure | -1,985.71% | 81.65% | 92.59% | 96.98% | 98.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,985.71% | 81.65% | 92.59% | 96.98% | 98.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.90% | 99.67% | 49.91% | 0.29% | -155.22% |
| Issuance of Common Stock | -46.46% | 633.97% | 16,027.72% | 16,406.76% | 17,352.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 252.62% | 946.32% | 545.74% | 492.14% | 728.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19,609.21% | 193.15% | 114.25% | 102.12% | 99.72% |